Latest NKT Therapeutics Inc. Stories
- Preclinical data demonstrating iNKT cell depletion reduces inflammation and improves organ function in a murine model of sickle cell disease WALTHAM, Mass., Dec.
-- Dosing in Phase 1b Trial Complete WALTHAM, Mass., Oct. 2, 2014 /PRNewswire/ -- NKT Therapeutics today announced that the U.S.
PARSIPPANY, N.J., Feb. 8, 2011 /PRNewswire/ -- DSM Biologics, a business unit of DSM Pharmaceutical Products, today announced the signing of a contract with NKT Therapeutics, Inc.
PRINCETON, N.J. and WALTHAM, Mass., Oct. 21 /PRNewswire/ -- BioWa, Inc. (BioWa) and NKT Therapeutics, Inc.
GENEVA, Sept. 1 /PRNewswire/ -- Selexis SA ("Selexis") and NKT Therapeutics, Inc.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.